FAQs

Tune in on Saturday 26 April–the day Nine Telethon supporting Mater Little Miracles will return to your screens and to your heart. 

At Mater, every baby born and cared for is affectionately known as a ‘little miracle’, however each year more than 1,700+ babies are born very ill or premature, which need round the clock care from a range of medical specialists.

Through the Nine Telethon, with the support of the community and the support of Channel Nine, Mater aims to raise critical funds towards life-saving research, care and equipment, ensuring all babies at Mater have the best possible start to life.

With the help of donations from the community, Mater clinicians and researchers can continue to improve outcomes for our tiniest and most vulnerable patients.

Mater Foundation is a community-based fundraising organisation that supports the work of Mater Health, Mater Education and Mater Research. 

Thanks to the generosity of supporters like you, Mater meets a profoundly satisfying mission to improve the health and wellbeing of our community and to continue the Mater tradition of care and compassion. 

Mater Foundation works towards improving health outcomes by funding ground-breaking research initiatives, purchasing state-of-the-art medical equipment, enhancing facilities, and supporting life changing healthcare programs.

Beyond the Nine Telethon, there are several options to support Mater. 

They include buying a ticket in a Mater Lottery, signing up for regular giving, leaving a Gift in Will to Mater Foundation, joining a community event or volunteering. 

To find out more about Mater Foundation and how you can get involved, visit materfoundation.org.au.

If you are interested in sharing your own personal Mater Little Miracle story, please fill out the contact us form with some information about your Mater journey and we will be in touch as soon as we can.

Through the generosity of communities across Queensland, the 2024 Nine Telethon raised an astonishing $6.86 million, enabling Mater clinicians and researchers to continue to improve outcomes for our tiniest and most vulnerable patients.